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Kerstin M Ahlgren*, Tina Ruckdeschel, Anders Eklund, Jan Wahlström and Johan GrunewaldAbstract
Background: Sarcoidosis patients have accumulations of activated CD4+ T cells in affected organs, such as the
lungs. T cell receptor (TCR) Vβ-chain usage has been incompletely characterized in these patients.
Methods: We surveyed the TCR Vβ usage in CD4+ and CD8+ T cells in bronchoalveolar lavage (BAL) cells and
peripheral blood mononuclear cells (PBMC) from 15 HLA-typed Scandinavian sarcoidosis patients. In addition, PBMC
from 9 healthy volunteers and BAL cells from three of them were examined. Using 21 Vβ family-specific antibodies,
we covered approximately 70% of all Vβ chains.
Results: In BAL T cells from sarcoidosis patients, we identified 16 CD4+ T cell expansions in 271 analyses (5.9%) and
21 CD8+ expansions in 240 analyses (8.7%). In PBMC we found 9 CD4+ expansions in 276 analyses (3.3%) and 12 CD8+
expansions out of 263 analyses (4.6%). Consistent with previous studies we found Vβ8 and Vβ16 expansions in
sarcoidosis patients’ lungs. In addition, we found lung restricted Vβ22 expansions in three HLA DRB1 03+ patients.
However, we found no statistically significant difference in frequency of expansions between patients and healthy
controls.
Conclusions: The identified T cell expansions in present study indicate specific antigen recognition in the lungs of
sarcoidosis patients.
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Sarcoidosis is a multisystem disorder characterized by an
accumulation of activated CD4+ T cells in the affected
organs [1]. In the majority of cases the lungs are targeted
by disease. Many of the patients suffer from respiratory
symptoms such as dyspnea, dry cough and chest pain.
Bronchoscopy with bronchoalveolar lavage (BAL) is com-
monly performed to examine patients exhibiting respira-
tory symptoms and clinical signs of sarcoidosis. BAL can
also be used as a research tool because the aspirate in-
cludes cells most likely relevant for the pathophysiology
[2]. From studies of BAL cells we know that lung accumu-
lated immune cells are activated in sarcoidosis patients
[3,4], further, accumulations of CD4+ cells expressing the* Correspondence: kerstin.ahlgren@ki.se
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reproduction in any medium, provided the orT cell receptor (TCR) V gene segment Vα2.3+ are accu-
mulated in BAL fluid (BALF) of HLA DRB1*03+ patients,
often with Löfgren’s syndrome [5].
Characterizations of TCR gene usage in lung and blood
of patients can provide insights into disease associated
processes [6-9]. T cell recognition of a particular antigen
presented by an HLA molecule can result in a clonal ex-
pansion of T cells bearing identical TCRs. The majority of
T cells express the αβ TCR. The variable (V) region of the
β-chain is generated by recombination through somatic
rearrangement of one V region gene to a D and a J seg-
ment selected from a pool of discontinuous gene seg-
ments. By RNA splicing the VDJ segment is put together
with one of the two C region genes. A similar principle ap-
plies to the α-chain, consisting of V and J segments. The
TCR V region genes are not randomly used within CD4+
and CD8+ T cells. There are several V α and β genes that
have a significant skewing to either CD4+ or CD8+ cellsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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region gene products with MHC II molecules (for CD4+
skewing), or MHC I (for CD8+), during thymic maturation
of the T cells. Hence, we analyzed these cell subsets sepa-
rately. Previous studies have assessed the TCR α and β
chain gene segments in sarcoidosis, mainly by PCR ampli-
fication [5,12-14].
The etiology of sarcoidosis is still not clear. Most evi-
dence supports a genesis including a trigger by one or
more still unknown antigens in the lungs and an aberrant
immune response in genetically susceptible individuals.
We hypothesise that antigenic triggering in the lungs of
patients would give rise to T cell clones expressing certain
Vβ-segments at higher frequency compared to the corre-
sponding frequency in blood.
In the present study we used flow cytometric analysis
of T cells stained with a large panel of 24 TCR Vβ
specific antibodies, covering about 70% of the normal
TCR Vβ repertoire in both CD4+ and CD8+ T cells. We
mapped the Vβ repertoire in BALF cells and peripheral
blood mononuclear cells from 15 patients with pulmon-
ary sarcoidosis, six of them with Löfgren’s syndrome.
Methods
Study subjects
BALF samples, and peripheral blood from all patients
but one, were obtained from 15 Scandinavian patients
(values show median age, with min- max range in paren-
thesis) [43 (30–74) years old; 7 women] coming to theTable 1 Characteristics of the sarcoidosis patients
Patient characterizations
Patient HLA DRB1 type CD4/CD8 ratio Lymphocytes in BA
1 4, 15 17 49
2 3 11.1 25
3 1, 3 1.8 6.6
4 NA 10.3 64
5 13, 14 11.8 34
6 4, 8 8.9 32
7 4, 15 7.3 16.8
8 1, 13 14.4 14.2
9 3, 16 11.3 25.6
10 3, 15 2.2 7
11 13, 15 3.6 12.4
12 4, 15 7.2 25.6
13 15 3 50
14 4, 7 2.4 7.6
15 4, 8 6 19
NA = not analysed, VC = vital capacity (% of reference value), FEV1 = forced expirato
monoxide. *Chest X-ray stages: I) Bilateral hilar lymphadenopathy (BHL) without pu
without BHL, IV) fibrosis with distortions.Respiratory Medicine unit at the Karolinska University
Hospital, Stockholm, Sweden, for diagnostic investigation
(as outlined in ref [1]). All patients included in the study
had an active disease with symptoms such as fatigue, dys-
pnea on exertion, and dry coughing, as well as findings on
chest radiography in line with sarcoidosis. All were inves-
tigated clinically and with pulmonary function tests, as
well as with bronchoscopy with bronchoalveolar lavage,
and were diagnosed with sarcoidosis according to criteria
established by World Association of Sarcoidosis and other
Granulomatous Disorders (WASOG) [15]. Blood from
9 healthy non-smoking volunteers [35 (18–51) years old; 7
women] and BALF from three of them were included as
controls. All subjects gave their informed consent. The
study was approved by the Regional Ethical Review Board
in Stockholm, Sweden. The clinical characterization is
outlined in Table 1. At the time of bronchoscopy none
had any systemic anti-inflammatory treatment. All sub-
jects undergoing BAL were HLA-typed.
BAL procedure and handling of cells
BAL was performed under local anaesthesia by an expe-
rienced physician as previously described [16]. In short,
a flexible fibreoptic bronchoscope was passed transo-
rally and wedged into the middle-lobe bronchus. Sterile
phosphate buffered saline at 37°C was instilled in five
aliquots of 50 ml and immediately re-aspirated and col-
lected into a siliconised plastic bottle kept on ice. The
mean recovery of the instilled fluid was 63% (min-maxPulmonary function tests
L (%) Chest X-ray stage* VC (%) FEV1 (%) DLco (%)
I 93 100 84
I 76 82
II 82 81 87
I 69 63 58
II 108 103 90




I 96 107 111
III 73 60 93
I 119 124 111
II 85 80
IV 65 62 55
III 99 86 78
ry volume in one second, DLco = diffusing capacity of the lung for carbon
lmonary infiltrates, II) BHL with pulmonary infiltrates, III) pulmonary infiltrates
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(Millipore, Cork, Ireland) before centrifugation. The cell
pellet was resuspended in cold phosphate buffered saline
(PBS) pH 7.4, and kept on ice throughout the experi-
ments. BAL fluid differential cell counts were based on
May-Grünwald and Giemsa staining (Table 2).
Peripheral blood mononuclear cells
Whole blood was collected into Sodium Heparinised
tubes. Peripheral blood mononuclear cells were isola-
ted using Ficoll Paque PLUS (GE Healthcare, Uppsala,
Sweden) according to the manufacturer’s instructions.
Flow cytometric analysis of Vβ repertoires
BAL and blood cells were stained using the following anti-
bodies; CD3-Pacific Blue (BD Pharmingen), anti CD4-
APC-H7, CD8-AmCyan (11 of 15 patient samples and all
control samles) (BD Bioscience). Normal mouse serum
(Corning Life Science, Tewksbury, MA, USA) was used as
Fc-Block. TCR Vβ was stained using an eight-tube panel,
containing 24 monoclonal antibodies known to react with
specific TCR-Vβ families (IO Test Beta Mark TCR Vβ
Repertoire Kit)(Beckman Coulter, Brea, CA, USA). Each
test, containing 1 million BAL cells or 0.5 million PBMC,
permitted analysis of three Vβ families simultaneously as
each of the eight tubes included a mixture of three anti-
bodies conjugated to fluorescein isothiocyanate, phyco-
erythrin or fluorescein isothiocyanate and phycoerythrin.
Due to limitations in cell numbers, all Vβ families were
not analysed in all subjects. Nomenclature for the Vβ
families used throughout this paper is from [17]. Flow
cytometry was run on a BD FACS Canto II. Results were
expressed as the percentage of CD4+ and CD8+ T cells,
respectively, that expressed the various TCR Vβ families.
Definition of T cell expansion and statistical analysis
T cell expansions were defined as in [18], i.e. any expres-
sion of a certain Vβ family as percentage of the gated
population (CD4+ or CD8+ T cells) > 2 SD above the ref-
erence value was considered a significant T cell expan-
sion. Reference values for the frequency of Vβ gene
segment found in CD4+ and CD8+ blood T cells of
healthy subjects (based on a cohort of 85 (or 46 for Vβ4,
Vβ7.2 and Vβ13.2) normal blood specimens) wereTable 2 Analysis of the bronchoalveolar lavage fluid
BALF characteristics Differentia
Percent recovery Total cell conc. (*106/L)c Lymphocy
Sarcoidosis
patientsa
68 (42–73) 153 (35–534) d
Healthy
controlsb
68 (48–71) 77 (62–106) 10 (5.7-11)
a)n = 15; b)n = 3; c)median (min- max range) d)see result section and Table 1.provided by the manufacturer of the test (Beckman
Coulter, Brea, CA, USA). The healthy control values in
this study were consistent with the reference values, ex-
cept for Vβ4, Vβ5.3 and Vβ9, which had a very low sig-
nal in all samples and Vβ12, which had a higher
expression in our CD8+ samples compared to reference
values on CD8+ cells (Additional file 1). Vβ4, Vβ5.3 and
Vβ9 were therefore excluded from all further analyses.
Since the normal TCR repertoire in BAL fluid has not
been extensively studied, the reference values obtained
from whole blood were also used for CD4+ and CD8+
BAL T cells.
Wilcoxons signed ranks test was used to calculate
differences in Vβ expression in lung and blood cells.
Fisher’s exact test was used to calculate difference in
frequency of expansions between groups. Differences with
p-values ≤ 0.05 were considered statistically significant.
Results
Patient characteristics
Fifteen patients with sarcoidosis were included. The sar-
coidosis diagnosis was made based on typical clinical and
radiographic manifestations [1] and findings at bron-
choscopy with BAL according to criteria as outlined by
WASOG [15]. Two patients had ocular sarcoidosis. Six
patients with Löfgren's syndrome, with typi cal acute onset
of disease and chest X-ray stage I-II were included in the
study. Four of them had erythema nodosum; none had
ankle arthritis (Table 1). In addition we were able to re-
cruit three healthy controls for BAL.
The majority of patients (73%) had a CD4/CD8 ratio
above 3.5 (median 7.3, min-max range 1.8-17), the BALF
contained 25% (median, min-max range 6.6-64 lympho-
cytes) and 8 patients included had chest X-ray stage I; four
of the patients stage II, two patients stage III and one stage
IV. Five patients were ex-smokers and one was current
smoker. Diffusing capacity of carbon monoxide (DLco)
had a statistically significant inverse correlation with the
number of CD8+ T cell expansions in BAL from sarcoi-
dosis patients (r = 0.85, p = 0.002, Spearman correlation).
No statistically significant correlation between number of
T cell expansions and other pulmonary functions tested
(VC and FEV1), chest X-ray stage, CD4/CD8 ratio, sex or
age were identified (Tables 1 and 2).l cell count
tes (%)c Macrophages (%)c Neutrophils (%)c Eosinophils (%)c
74 (30–92) 1.0 (0.2-3.4) 0.0 (0–3.0)
88 (88–89) 1.3 (0.7-5) 0.0 (0–0.4)
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healthy controls
To determine whether there is biased expression of TCR
Vβ segments in CD4+ cells in sarcoidosis, a panel of 24
antibodies covering approximately 70% of the TCR Vβ
repertoire was tested on 15 patients. In CD4+ BAL cells
16 T cell expansions were identified from 271 analyses
(5.9%) (Figure 1A). These T cell expansions appeared in
eleven of the 21 studied TCR Vβ chains (Table 3). In CD4+
PBMCs, 9 T cell expansions in 6 different Vβ families,
were identified of 276 analyses (3.3%) (Figure 1B).
We found two patients with CD4+ Vβ8 expansions, one
of which contained as many as 45.6% of the CD4+ cells.
These expansions were not lung restricted, but appeared
in the PBMC. In another two patients the Vβ8 segment
was expressed as expansions in the lung, however in CD8+
T cells. Vβ12 was expressed as expansions in the CD4+
population in both lung (two patients) and blood (two
patients) (Table 3). Vβ5.1 and Vβ22 CD4+ BAL cell expan-
sions were found in two and three patients, respectively
(Figure 1A). These expansions seem to be lung restricted.
We identified one TCR Vβ2, two Vβ12 and two Vβ16


























































































Figure 1 TCR Vβ expansions in CD4+-BAL (A) and PBMC (B). Each circle
more expansions (filled circles) of CD4+ T cells expressing a particular Vβ g
expressed as T cell expansions in two patients each, Vβ22 in three patients
expansions in one patient each. In PBMC (B) 6 patients had T cell expansio
were expressed as expansions in one patient each; segments Vβ8, Vβ12 an
of T cell expansion was > mean plus two* SD of a cohort of healthy controIn BAL from three healthy controls we identified six
expansions in CD4+ BAL cells, in 63 analyses (9.5%)
(Table 3). These expansions consisted of TCR Vβ13.1,
Vβ13.2 (n = 2), Vβ13.6, Vβ16 and Vβ23. We found no
significant difference in the frequency of expansions bet-
ween sarcoidosis patients and controls in CD4+ cells
(BAL p =0.17; PBMC p = 0.95).
Vβ repertoire in CD8+ T cells of sarcoidosis patients and
healthy controls
The expression of TCR Vβ segments in CD8+ cells in
sarcoidosis patients was analyzed in the same way as the
CD4+ cells. There were 21 T cell expansions expressing
distinct Vβ segments out of 240 analyses in CD8+ BAL
cells (8.7%) (Figure 2A) and 12 T cell expansions out of
263 analyses in PBMC (4.6%) (Figure 2B). Three patients
had a T cell expansion of cells harboring the Vβ16 seg-
ment in CD8+ BAL cells. Also in PBMC CD8+ cells four
Vβ16 T cell expansions appeared, but not in the same
individuals as those having Vβ16 expansions in the lung
compartment (Table 3). Out of 181 analyses of Vβ usage























































indicates a sample from one patient. Nine of the patients had one or
ene segment in the BAL fluid (A). Vβ5.1, Vβ12 and Vβ16 were
; Vβ1, Vβ2, Vβ13.1, Vβ13.2, Vβ17, Vβ18 and Vβ23 were expressed as
ns expressing a particular Vβ gene segment. Vβ2, Vβ7.2 and Vβ13.1
d Vβ20 were expressed as expansions in two patients each. (Definition
ls subjects).
Table 3 TCR Vβ expansions in BAL and PBMC indicating CD4+ or CD8+ expansions and patient and control id with HLA
DRB1 type
TCR Vb BAL cells Patient/Ctrl HLA PBMC Patient/Ctrl HLA
Vb1 CD4 P 6 4, 8 CD8 P 1 4, 15
CD8 P 4
CD8 P 5 13, 14
CD8 P 9 3, 16
CD8 Ctrl 9 4, 15
Vb2 CD4 P 1 4, 15 CD4 P 5 13, 14
CD8 P 6 4, 8 CD4 Ctrl 8 12, 15
CD8 Ctrl 9 4, 15
Vb5.1 CD4 P 13 15
CD 4 P 15 4, 8
Vb5.2 CD8 Ctrl 6
Vb7.1 CD8 P 14 4, 7
Vb7.2 CD8 P 2 3 CD4 P 7 4, 15
Vb8 CD8 P 13 15 CD4 P 3 1, 3
CD8 P 14 4, 7 CD4 P 7 4, 15
Vb11 CD8 P 13 15 CD8 P 3 1, 3
P 4 P 4
Vb12 CD4 P 8 1, 13 CD4 CD8 P 5 13, 14
CD4 P 15 4, 8 CD4 P 6 4, 8
CD8 P 1 4, 15 CD8 P 1 4, 15
CD8 P 6 4, 8 CD8 P 2







Vb13.1 CD4 P 13 15 CD4 P 3 1, 3
CD4 Ctrl 9 4, 15 CD8 P 3 1, 3
P 5 13, 14
Vb13.2 CD4 P 13 15 CD8 P 13 15 15
CD8 P 6 4, 8
CD4 Ctrl 8
CD4 Ctrl 9 4, 15
Vb13.6 CD8 P 13 15
CD4 Ctrl 8 12, 15
CD8 Ctrl 7 7, 16
CD8 Ctrl 8 12, 15
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Table 3 TCR Vβ expansions in BAL and PBMC indicating CD4+ or CD8+ expansions and patient and control id with HLA
DRB1 type (Continued)
Vb16 CD4 P 3 1, 3 CD8 P 1 4, 15
CD4 P 15 4, 8 CD8 P 2 3
CD8 P 6 4, 8 CD8 P 5 13, 14
CD8 P 12 4, 15 CD8 P 11 13, 15
CD8 P 13 15 CD4 Ctrl 2
CD4 Ctrl 7 7, 16 CD4 Ctrl 4
CD8 Ctrl 7 7, 16 CD8 Ctrl 2
CD8 Ctrl 8 12, 15 CD8 Ctrl 3
Ctrl 4
Ctrl 9 4, 15
Vb17 CD4 P 15 4, 8 CD8 Ctrl 5
CD8 Ctrl 8 12, 15
Vb18 CD4 P 12 4, 15
Vb20 CD4 P 1 P 1 4, 15
CD4 P 13 P 13 15
Vb21.3 CD8 P 2 3
Vb22 CD4 P 2 3
CD4 P 3 1, 3
CD4 P 9 3, 16
CD8 P 4
CD8 P 15 4, 8
Vb23 CD4 P 3 1, 3
CD8 P 3 1, 3
CD4 Ctrl 9 4, 15
BAL PBMC
a CD4 CD8 CD4 CD8
Patients 16/271 (5.9%) 21/240 (8.7%) 9/276 (3.3%) 12/263 (4.6%)
Controls 6/63 (9.5%) 6/63 (9.5%) 5/187 (2.7%) 11/181 (6.1%)
a) Number of expansions per analysis.
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in CD4+ and CD8+ cells
In order to assess whether a bias for TCR Vβ was associ-
ated with compartmentalization to the lungs or blood of
sarcoidosis patients, we performed a comparison bet-
ween the Vβ expression in lung and PBMC. There were
six Vβ segments with significantly different expressions
comparing lung and blood (Figure 3). The segments
Vβ3, Vβ7.2, Vβ8, Vβ11, Vβ14 and Vβ18 had a statisti-
cally significantly higher (p < 0.05) expression in blood
compared to lung. However, we found no segments that
had a significantly higher expression in CD4+ cells in the
lung compartment compared to blood. In CD8+ cells,
TCR Vβ13.6 has a statistically significantly higher expres-
sion in lungs than blood of sarcoidosis patients (p = 0.009)
(Figure 4). Comparing the number of T cell expansions,
the difference in frequency of CD4+ TCR Vβ T cellexpansions in lung vs. blood of sarcoidosis patients (p =
0.56) or controls (p = 0.12) was not statistically significant.
Neither were there statistical differences in frequency of
CD8+ TCR Vβ expansions in lung than in blood of sar-
coidosis patients (p = 0.15) or controls (p = 0.45).
However, directly comparing the frequencies of accu-
mulated cells with the individual Vβ segments, i.e. without
regard to the Vβ usage being classified as an expansion or
not, and setting an arbitrary cut off difference between
lung and blood compartments of 5%, we identified dif-
ferences in 8 different segments in the CD4+ population
(Figure 5A). Three of them appeared in Vβ22. This was
also the only segment repeatedly found with a higher
value in CD4+ BAL cells than PBMC. Segments Vβ2 and
Vβ8 had a greater percentage in blood than lung in two
patients each. Contrary, one of the other patients (Pa-






































































































































Figure 2 TCR Vβ expansions in CD8+-BAL (A) and PBMC (B). Each circle indicates a sample from one patient. Eleven of the patients had one
or more expansions (filled circles) of CD8+ T cells expressing a particular Vβ gene segment in the BAL fluid. In BAL (A) Vβ2, Vβ7.1, Vβ7.2, Vβ11,
Vβ13.2, Vβ13.6, Vβ21.3 and Vβ23 were expressed as T cell expansions in one patient each, Vβ8 and Vβ22 in two patients each and Vβ12 and Vβ16
in three patients. In PBMC (B) Vβ1 and Vβ13.2 were expressed as expansions in on patient each, Vβ11, Vβ12 and Vβ13.1 in two patients each and
Vβ16 in four patients. (Definition of T cell expansion was > mean plus two* SD of a cohort of healthy controls subjects).
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(6.1%) analyses displayed a greater difference between
lung and blood Vβ-gene segment expression than 5%, in
any direction. There were 10 different segments in the
CD8+ cells with differences exceeding 5% in expression
between lung and blood (Figure 5B). In CD8+ T cells
Vβ1 and Vβ2 had a more than 5% higher expression in
lung T cells compared to in PBMC in two patients each.
Both these segments also had higher expression in
blood compared to lung in one patient each. Eight Vβ
segments had a higher expression in CD8+ PBMC than
CD8+ lung T cells, and seven had higher expression in
lung than blood CD8+ cells. These differences did how-
ever not appear in more than one patient each. In the
CD8+ T cells, 17 of 220 (7.7%) analyses displayed greater
difference between lung and blood Vβ-gene segment ex-
pression than 5%, in any direction.
Vβ-repertoire in patients with different disease
manifestations and HLA DRB1 alleles
There was no statistically significant difference in fre-
quency of expansions between patients with or without
Löfgren’s syndrome, patients with or without erythema
nodosum or ocular sarcoidosis, or between CD4+ and
CD8+ cells in sarcoidosis patients (p > 0.05, Fisher’s exact
test). 14 of 15 patients were HLA DRB1-typed. In BAL
cells, three patients with CD4+ Vβ22 expansions wereHLA DRB1*03+. Two of these three patients had Löfgren’s
syndrome. There were three HLA DRB1*04+ patients with
CD8+ Vβ12 expansions. One of these patients had ockular
sarcoidosis and one Löfgren’s syndrome with erythema
nodosum.
Discussion
Knowledge about TCR gene segment expression in sar-
coidosis can provide insights to the pathogenic process
and assist the finding of a potential disease triggering anti-
gen. Previous studies aimed at mapping the TRC Vα and
Vβ repertoire has often used PCR technique [5,12-14].
This technique permit analysis of all Vβ gene segments,
however not simultaneously in different populations such
as CD4+ and CD8+ cells. The PCR technique does not, in
contrast to use of monoclonal antibodies and flow cyto-
metry, measure the expression at the protein level. The
latter method is the only method to analyze individual
cells Vβ usage. Over time the number of available mono-
clonal antibodies specific for TCR Vβ family members has
increased, now allowing approximately 70% of the TCR
Vβ repertoire to be mapped. This led us to the use of
monoclonal antibodies directed to TCR Vβ-chain proteins
and flow cytometry for the present study. Our major fin-
ding was that expansions of T cells expressing Vβ5.1,
Vβ7.1, Vβ18, Vβ21.3 and Vβ22 were found only in BAL



































































































































Figure 3 Differences in Vβ usage between CD4+ T cells in BAL cells and PBMC. Comparisons between TCR Vβ segment expression in lung and
blood revealed a statistically significantly higher expression of segments Vβ3, Vβ7.2, Vβ8, Vβ11, Vβ14 and Vβ18 in blood than lung. (* p <0.05, ** p < 0.01,
Wilcoxon’s signed ranks test).
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in present study. Vβ16 TCR expansion has previously
been described to appear in sarcoidosis patients [12].The patients in our study all had respiratory symptoms,
leading to BAL as a part of the clinical examination. This






















Figure 4 Higher Vβ13.6 usage in CD8+ BAL cells compared to
PBMC. Comparisons between TCR Vβ segment expression in CD8+
T cells in lung and blood revealed a statistically significantly higher
expression of segment Vβ13.6 in lung than blood in sarcoidosis















































































































Figure 5 Vβ segments with absolute usage difference between
BAL cells and PBMC. Each dot indicates difference, BAL vs. PBMC, in
one Vβ segments in one patient. The expression (% of the gated
population) in PBMC was subtracted from the expression in BAL. Positive
values indicate a greater expression in BAL and negative values indicate
a greater expression in PBMC. The arbitrary cut off > 5% difference is
indicated by a dotted line. A) In CD4+ T cells 9 Vβ segments had > 5%
higher or lower expression in BAL cells versus PBMC in at least one
patient. Segments with higher expression in BAL were Vβ1, Vβ17 and
Vβ22, while segments Vβ3, Vβ8, Vβ13.1 had higher expression in PBMC.
Segment Vβ2 had higher expression in BAL in one patient and higher
expression in PBMC in two other patients; Vβ5.1 had higher expression
in BAL in one patient and in PBMC in another patient. B) In CD8+ T cells
10 Vβ segments had > 5% difference in expression comparing BAL cells
and PBMC in at least one patient. Vβ1 and Vβ2 both had higher
expression in BAL from two patients and in PBMC in one patient. Vβ7.1
and Vβ7.2 had higher expression in BAL in one patient each; Vβ8, Vβ13.2
and Vβ16 had higher expression in BAL in one patient and higher
expression in PBMC in another patient each, and the segments Vβ11,
Vβ12 and Vβ13.1 had higher expression in PBMC in one patient each.
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ments in sarcoidosis patients revealed that the expression
in the blood, with a few exceptions, exceeded the expres-
sion in the lungs. Reference values were provided by the
manufacturer of the antibodies. These are based on the
Vβ-repertoire in blood lymphocytes from a cohort of
healthy subjects, of Mediterranean heritage. In previous
studies we have used the definition of a T cell expansion
as three times the reference value, or any value above 15%
of the gated population. However, since this definition
may in fact underestimate T cell expansions we defined a
T cell expansion as in a recent study on sporadic inclusion
body myositis [18], which defines an expansion as above
the reference value plus two SD. Comparing TCR Vβ
repertoires in lung and blood, similarities rather than
generalized skewing have previously been described [19].
Therefore we used the same reference values for BAL as
PBMC. When the total repertoire in each patient was
added together and compared to the reference values, we
did however note a lower expression in the CD4+ BAL
cells than in the CD4+ PBMCs (data not included). This
may indicate a higher normal expression in BAL cells, of
certain Vβ segments that is not targeted by the assay in
this study.
A higher variability in TCR Vβ expression in CD8+
cells than CD4+ cells is consistent with previous findings
in healthy controls and other diseases [9]. Somewhat
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ber of expansions between CD8+ cells and CD4+ cells or
between sarcoidosis patients and controls in present
study.
In three patients that were positive for the HLA II
allele DRB1*04 we identified TCR Vβ 12 expansions in
the CD8+ cell population. However, the CD8 molecule
is not interacting with HLA II molecules, but with HLA
I molecules. To our knowledge there is no association
between HLA DRB1*04 and any HLA class I allele.
Vβ12 was the segment most frequently found as T cell
expansion in present study. However, our control blood
donors displayed a significantly higher Vβ12 expression
in CD8+ cells than the reference values, suggesting that
this may not be a sarcoidosis specific expansion, and
may be caused by local deviation from the reference co-
hort. The reason for this deviation may be the genetic
difference between the reference cohort, which is of
Mediterranean origin, and our Swedish controls, or due
to yet unidentified reasons. The healthy controls in
present study were not HLA typed.
Vβ22 expansions were found in CD4+ T cells of three
patients, all being HLA DRB1*03 positive. These expan-
sions moreover, were lung restricted. HLA DRB1*03 and
TCR Vβ22 expansion has previously been described in
the context of inflammatory disease, albeit at a lower
frequency. In a small study, three out of 9 patients, all
three HLA DRB1*03 positive, with Idiopathic Inflamma-
tory Myopathies [6] four Vβ22 T cell expansions were
identified. Two of these were located in CD3+ cells in
muscle, one in CD8+ BAL cells and one in CD4+ peri-
pheral blood cells.
In a previous report Moller et al. described a biased
usage of Vβ8 in sarcoidosis patients’ lung T cells, and to
a lesser degree in blood [20]. Consistent with our pre-
vious study [13] and a study by Forman et al. [12] in
1994, we noted Vβ8 T cell expansions in BAL in sarcoi-
dosis patients in this study. In the present study we also
noted Vβ8 T cell expansions in CD4+ PBMC of two sar-
coidosis patients.
Vβ5.1 and Vβ22 were the only two Vβ segments
appearing exclusively as CD4+ T cell expansion in BAL
from more than one sarcoidosis patients. Both these seg-
ments have been shown to associate with other diseases,
such as oral lichen planus and angioimmunoblastic
T cell lymphoma [21-23].
We identified CD8+ Vβ16 T cell expansions in five sar-
coidosis patients, of which three were located in the lung
compartment. This TCR expansion has previously been
described by Forman et al. to appear in sarcoidosis pa-
tients [12]. It was not investigated whether these expan-
sions appeared in CD4+ or CD8+ cells. However, equally
to Vβ12 in present study, our healthy controls had a
higher expression of Vβ16 than the reference values.It is known from our previous studies that T cell accu-
mulations tend to withdraw after spontaneous resolution
of clinical and radiographic signs of disease in HLA
DRB1*03+ sarcoidosis patients with Vα2.3 accumulations
[3]. Potentially some clonal expansions may already have
resolved. The exact disease onset is not possible to de-
termine, but the BAL was in all cases performed as a
part of the diagnostic investigation.
Conclusions
The TCR repertoire is shaped by processes during T cell
maturation and exposure to environmental antigens.
One pathogen can consist of hundreds of proteins,
which each can be broken down to many peptides that
are presented in different ways depending on the MHC-
molecules on APCs they are presented by. Therefore,
even a single specific protein antigen has the potential to
give rise to several different Vβ T cell expansions.
Further studies analyzing the T cell responses to candi-
date antigens and Vβ-repertoire are thus warranted. In the
present study we also looked for associations between
HLA DRB1 alleles and T cell expansions. However, due to
the small sample size only cautious conclusions can be
drawn. Further studies could strengthen our conclusion
that Vβ8 and Vβ16 T cell expansions are associated to sar-
coidosis and Vβ22 associated to the HLA DRB1*03 allele.
Our present results extend the knowledge from the
previous studies. This may in the future improve predic-
tions on disease progression and lead to a more indivi-
dual approach for treatment.
Additional file
Additional file 1: The healthy control values in this study were
compared with reference values. The values of our Swedish cohort is
consistent with the reference values, except for Vβ4, Vβ5.3 and Vβ9,
which had a very low signal in all samples and Vβ12, which had a higher
expression in our CD8+ samples compared to reference values on CD8+
cells. Vβ4, Vβ5.3 and Vβ9 were therefore excluded from all further
analyses. Since the normal TCR repertoire in BAL fluid has not been
extensively studied, the reference values obtained from whole blood
were also used for CD4+ and CD8+ BAL T cells.
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